Price/Sales of Coherus BioSciences, Inc.
The price to sales ratio, Price/Sales ratio, P/S ratio, or PSR, is a valuation metric for stocks. It is calculated by dividing the company's market cap by the revenue in the most recent year. It can also be calculated by dividing the per-share stock price by per-share revenue. The price to sales ratio is for trailing twelve months so the reported sales are for the four previous quarters. Longer time periods can be examined at times.
A smaller price to sales ratio is usually thought to be a better investment since the investor is paying less for each unit of sales. However, sales do not reveal the whole picture, as the company may be unprofitable with a low P/S ratio. Because of the limitations, this ratio is usually used only for unprofitable companies, since they don't have a price to earnings ratio (P/E ratio). The metric can be used to determine the value of a stock relative to its past performance. It may also be used to determine relative valuation of a sector or the market as a whole.
Price to sales ratios vary greatly between sectors, so they are most useful in comparing similar stocks within a sector or sub-sector. Comparing P/S ratios carries the implicit assumption that all firms in the comparison have an identical capital structure.
Coherus BioSciences, Inc., a late-stage clinical biologics platform company, focuses on developing and commercializing biosimilar products worldwide. The company's product candidates include CHS-1701, a pegfilgrastim biosimilar candidate, which is used for the treatment of febrile neutropenia; CHS-0214, an etanercept biosimilar candidate, which is in various phases of clinical trials for the treatment of ankylosing spondylitis, juvenile idiopathic arthritis, psoriatic arthritis, rheumatoid arthritis, and psoriasis; and CHS-5217, a bevacizumab biosimilar candidate, which is in preclinical stage for the treatment of metastatic colorectal cancer, non?small cell lung cancer, metastatic kidney cancer, advanced cervical cancer, platinum-resistant ovarian cancer, and recurrent glioblastoma. Its product candidates also comprise CHS-1420, an adalimumab biosimilar candidate, which is in various phases of clinical trials to treat ankylosing spondylitis, Behçet's Disease, Crohn's Disease, juvenile idiopathic arthritis, psoriasis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis; and CHS-3351, a ranibizumab biosimilar candidate, which is in preclinical stage for the treatment of neovascular (wet) age-related macular, degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy. Coherus Biosciences, Inc. has license agreement with Daiichi Sankyo Company, Limited; Baxalta Incorporated, Baxalta US Inc., and Baxalta GmbH; Genentech, Inc.; and Selexis SA. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus Biosciences, Inc. in April 2012. Coherus Biosciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.
|ADVM Adverum Biotechnologies, Inc.||NASDAQ > Health Care > Biotechnology: Biological Products (No Diagnostic Substances)||178.78|
|SNDX Syndax Pharmaceuticals, Inc.||NASDAQ > Health Care > Major Pharmaceuticals||189.52|
|SCYX SCYNEXIS, Inc.||NASDAQ > Health Care > Major Pharmaceuticals||192.25|
|ASMB Assembly Biosciences, Inc.||NASDAQ > Health Care > Major Pharmaceuticals||200.56|
|TPHS Trinity Place Holdings Inc.||NYSEMKT > Consumer Services > Building operators||201.35|
|SYRS Syros Pharmaceuticals, Inc.||NASDAQ > Health Care > Major Pharmaceuticals||229.04|
|CHRS Coherus BioSciences, Inc.||NASDAQ > Health Care > Biotechnology: Biological Products (No Diagnostic Substances)||238.12|
|LJPC La Jolla Pharmaceutical Company||NASDAQ > Health Care > Biotechnology: Biological Products (No Diagnostic Substances)||8,824.21|
|RARE Ultragenyx Pharmaceutical Inc.||NASDAQ > Health Care > Major Pharmaceuticals||10,880.38|
|RIOT Riot Blockchain, Inc||NASDAQ > Health Care > Biotechnology: In Vitro & In Vivo Diagnostic Substances||14,181.75|
|ADMS Adamas Pharmaceuticals, Inc.||NASDAQ > Health Care > Major Pharmaceuticals||22,090.90|
|GLYC GlycoMimetics, Inc.||NASDAQ > Health Care > Major Pharmaceuticals||26,375.14|
|PRKR ParkerVision, Inc.||NASDAQ > Technology > Radio And Television Broadcasting And Communications Equipment||91,633.80|